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Abstract 
 
Genetic alterations that potentiate PI3K signalling are frequent in prostate cancer, yet how 
different genetic drivers of the PI3K cascade contribute to prostate cancer is unclear. Here, we 
report PIK3CA mutation/amplification correlates with poor prostate cancer patient survival. To 
interrogate the requirement of different PI3K genetic drivers in prostate cancer, we employed 
a genetic approach to mutate Pik3ca in mouse prostate epithelium. We show Pik3caH1047R 
mutation causes p110-dependent invasive prostate carcinoma in-vivo. Furthermore, we report 
PIK3CA mutation and PTEN loss co-exist in prostate cancer patients, and can cooperate in-
vivo to accelerate disease progression via AKT-mTORC1/2 hyperactivation. Contrasting single 
mutants that slowly acquire castration-resistant prostate cancer (CRPC), concomitant Pik3ca 
mutation and Pten loss caused de-novo CRPC. Thus, Pik3ca mutation and Pten deletion are 
not functionally redundant. Our findings indicate that PIK3CA mutation is an attractive 
prognostic indicator for prostate cancer that may cooperate with PTEN loss to facilitate CRPC 
in patients.  
 
Statement of significance  
We show PIK3CA mutation correlates with poor prostate cancer prognosis and causes prostate 
cancer in mice. Moreover, PIK3CA mutation and PTEN loss co-exist in prostate cancer, and 
can cooperate in-vivo to accelerate tumorigenesis and facilitate CRPC. Delineating this 
synergistic relationship may present new therapeutic/prognostic approaches to overcome 
castration/PI3K-AKT-mTORC1/2 inhibitor resistance. 
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Introduction 
 
Prostate cancer is the second most common male cancer-related death world-wide, 
emphasizing the failure of mainstay therapeutic regimens to treat advanced disease(1). A 
pivotal constraint for prostate cancer research is the lack of diverse in vivo models that 
accurately reflect the clinic. Expanding the range of prostate cancer models that display key 
clinicopathological characteristics is vital to; (i) delineate the complex molecular mechanisms 
underpinning prostate cancer, (ii) identify novel prognostic markers and therapeutic targets, 
and (iii) accurately establish the efficacy of novel therapies that are urgently needed in the 
clinic. 
 
Class 1A phosphatidylinositol 3-kinases (PI3Ks) are heterodimers consisting of a regulatory 
subunit encoded by PIK3R1 (p85/p55α/p50α), PIK3R2 (p85β) or PIK3R3 (p85γ), and a 
catalytic subunit encoded by PIK3CA (p110 PIK3CB (p110or PIK3CD (p110)(2,3). 
Upon activation of receptor tyrosine kinases (RTKs), G-protein coupled receptors (GPCRs) or 
RAS, PI3K is recruited to the membrane. Here, PI3K catalyses the generation of the second 
messenger phosphatidylinositol(3,4,5)trisphosphate (PIP3), which recruits the serine threonine 
kinases AKT (Protein kinase B, PKB) and Phosphoinositide-dependent kinase-1 (PDK1) to the 
membrane, as well as a plethora of  other PIP3 binding proteins (4). The first identified, and 
most well studied, PIP3 effector is AKT(4). PDK1 phosphorylates AKT at Thr308, leading to 
phosphorylation of downstream targets including Tuberous Sclerosis Complex 2 (TSC2) that 
activates mTOR complex-1 (mTORC1) to promote proliferation, survival and migration(2,3). 
Phosphorylation of AKT at both Ser473 and Thr308 is required for the full activation of AKT, 
and has been linked to co-activation of the mTORC1 and mTOR complex-2 (mTORC2) 
pathways(5). Key substrates of mTORC2 include AKT at Ser473(5), and serum/glucocorticoid 
regulated kinase-1 (SGK1), which phosphorylates and inactivates the metastasis suppressor N-
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Myc down-regulated gene-1 (NDRG1/DRG1/CAP43)(6). AKT dephosphorylation by PH 
domain leucine-rich repeat protein phosphatase (PHLPP) at Ser473 and Protein phosphatase 2 
(PP2A) at Thr308 deactivate AKT(5). The fine tuning of AKT phosphorylation levels mediates 
AKT pathway activity and subsequent cellular events. In addition, the tumor suppressor 
Phosphatase and tensin homolog (PTEN) serves to negatively regulate the PI3K cascade by 
catalysing the dephosphorylation of PIP3 to phosphatidylinositol 4,5-bisphosphate (PIP2). 
PTEN also mediates lipid phosphatase-independent tumor suppressor activities via its protein 
phosphatase domain(2).    
 
PI3K pathway hyperactivation is invariably associated with prostate cancer progression in the 
clinic, thus presenting an attractive therapeutic target. Indeed, loss of PTEN, a negative 
regulator of the PI3K pathway, is estimated to occur in 40-50% of prostate cancer patients(7,8). 
However, PI3K pathway hyperactivation can occur via a range of mechanisms (e.g. PIK3CA 
oncogenic mutation) that can independently influence downstream signaling events. We sought 
to determine if genetic drivers of the PI3K pathway that are present in prostate cancer, but have 
not been investigated previously, can also contribute to prostate cancer initiation/progression. 
To this end we generated a new, clinically relevant genetically modified mouse model 
harbouring a heterozygous activating mutation in Pik3ca specifically within prostate epithelial 
cells, and compared prostate histopathology with the well-characterised Pten-deleted mouse 
model of prostate cancer(9). Overall, our findings emphasize the prognostic value of PI3K 
genetic drivers to better inform personalised therapy design. 
 
Results 
 
 
PIK3CA mutation/amplification correlates with advanced prostate cancer progression. 
PIK3CA oncogenic mutation and amplification, which may increase p110 PI3K catalytic 
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activity, are frequently detected in human cancers (10-13). To better understand the frequency 
of PIK3CA alterations in prostate cancer, we analysed nine prostate cancer genomic datasets 
for PIK3CA mutations and gene amplification(14). Our analysis shows that PIK3CA mutations 
occur in up to 4% of prostate cancer patients, while PIK3CA copy number gain/amplification 
occurs in as many as 62% of cases (Fig.1A, Supplementary Table 1). PIK3CA mutations were 
predominantly nucleotide missense substitutions (87.5%, Supplementary Fig.1A) within the 
helical (44.1%) and kinase (20.6%) domains, and previously reported hotspot mutations in 
exon 9 (E542K, E545K) and 20 (H1047R)(10-12,15) were most frequent (Fig.1B). Notably, 
the majority of PIK3CA mutations observed (83%, 19/23) have been previously detected in 
prostate or non-prostate malignancies(12,13,15,16), and are reported to increase p110 
activity(12,15-18) (Fig.1B).  
 
To determine if PIK3CA mutation/amplification correlates with prostate cancer progression, 
we analysed the TCGA provisional prostate cancer dataset (Supplementary Table 2). Our 
analysis revealed that PIK3CA mutation and copy number gain/amplification frequency 
significantly correlates with poor prostate cancer survival, regional lymph node metastasis, and 
a higher pT category and Gleason grade (Fig.1C, Supplementary Table 3), resembling PTEN 
loss (Supplementary Fig.1B, Supplementary Table 4).  
 
Co-expression analysis within the nine prostate cancer datasets analysed revealed that 39.4% 
(13/33 patients) of PIK3CA mutation carriers also harboured PTEN mutation or copy number 
loss, indicating that PIK3CA mutant prostate cancer patients have a high frequency of co-
existent PTEN deleterious genetic alterations, consistent with ovarian, breast, endometrial, and 
colorectal cancer studies(11,19,20). Interestingly, 47.5% (96/202) of prostate cancer patients 
with PIK3CA amplification/gain also carried a PTEN mutation or copy number loss. Moreover, 
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statistical analysis of the larger TCGA provisional dataset revealed a significant tendency 
towards PIK3CA mutation/amplification/gain and PTEN mutation/loss co-occurrence in 
prostate cancer patients (P<0.001, Fisher’s exact test, Log odds ratio = 0.916). Together, these 
findings suggest that PIK3CA mutation/amplification/gain play an oncogenic role during 
prostate cancer and indicate that p110 gain-of-function and PTEN loss may cooperate to 
promote prostate cancer growth.  
 
Pik3caH1047R mutation in mouse prostate epithelium causes locally invasive prostate 
carcinoma. To delineate the oncogenic role of a clinically relevant PIK3CA mutation within 
the prostate, we inter-crossed mice that harbor a conditional latent H1047R mutation in Pik3ca 
to the PBiCre transgenic line. Using an exon-switch Cre-LoxP approach, expression of 
Pik3caH1047R was driven specifically within the prostate following PBiCre-mediated excision 
of the floxed wild-type (Wt) Pik3ca exon 20 and subsequent expression of a latent downstream 
mutant exon 20(11,21). Recombination was confirmed by sequencing and allele-specific PCR 
analysis of cDNA isolated from the prostate glands of PBiCre+/-;Pik3ca+/+ and PBiCre+/-
;Pik3ca+/Lat-H1047R mice, hereafter referred to as Wt and Pik3ca+/HR respectively (Supplementary 
Fig.2A-B). Histological analysis of Wt and Pik3ca+/HR prostate lobes revealed no gross 
phenotype in Wt mice, whereas Pik3ca+/HR cohorts displayed a progressive malignant 
phenotype. Pik3ca+/HR mice developed multifocal simple and/or cribriform hyperplasia in all 
prostate lobes by 100 d and homogeneous, locally invasive prostate carcinoma by 300–400 d 
(dorsolateral lobe: Fig.2A-B, and ventral/anterior lobes: Supplementary Fig.2C-E, 
Supplementary Table 5). Invasion was confirmed by the absence of smooth muscle actin 
(SMA) staining by immunohistochemistry (IHC) (Supplementary Fig.2F).  Pik3ca+/HR prostate 
carcinomas were predominantly dysplastic/mucinous and reactive stroma and immune 
infiltrate were evident (Fig.2A; 300-400 d, Supplementary Fig.2C). Taken together, these data 
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demonstrate that heterozygous Pik3caH1047R oncogenic mutation is sufficient to cause invasive 
prostate cancer in mice, and to our knowledge is the first example of a mono-allelic mutation 
driving invasive prostate cancer growth in vivo. 
 
To determine if the genetic driver of the PI3K cascade influences prostate tumorigenesis and/or 
malignant progression, we compared our novel Pik3ca+/HR prostate cancer model with the well-
characterised Pten-deleted mouse model of prostate cancer(9). To this end, we generated age-
matched cohorts of PBiCre+/-;Ptenfl/fl mice (denoted Ptenfl/fl) deficient for both copies of Pten 
within prostate epithelial cells and compared the phenotype on the same genetic background. 
In contrast to Pik3ca+/HR mice, we observed early onset of hyperplastic lesions at 56 d and rapid 
tumor progression from prostate intraepithelial neoplasia (PIN) to locally invasive carcinoma 
in Ptenfl/fl mice by 200 d (Fig.2A-B, Supplementary Fig.2C-E, Supplementary Table 5). 
Furthermore, Ptenfl/fl prostate tumor burden was significantly greater and more heterogenous 
than the Pik3ca+/HR model (Fig.2A/C), as carcinosarcomas were also present by 300 d in 29% 
of the cohort (2/7). However, metastasis to the liver, lung, lymph nodes or bone was not 
detected in either model. Ptenfl/fl mice were also prone to seminal vesicle neoplasia, urethra 
neoplasia and adrenal pheochromocytoma that were rare, or absent, in Pik3ca+/HR mice 
(Supplementary Table 5). These findings indicate that relative to the Pik3ca+/HR model, early 
disease onset, and potentially accelerated progression, contribute to the earlier emergence of 
invasive carcinoma in Ptenfl/fl mice.  
 
To investigate if Pten bi-allelic loss accelerates prostate tumor growth compared to Pik3ca+/HR-
driven prostate cancer, we performed and quantitated IHC to detect the S-phase proliferation 
marker PCNA. Pik3ca+/HR prostate disease (100–400 d) showed a significant increase in the 
number of PCNA-positive proliferating cells compared to Wt controls, however a clear 
Pik3ca mutation drives prostate cancer 
9 
 
proliferation advantage was evident in Ptenfl/fl mice between 56–200 d (Fig.3A-B). 
Furthermore, significantly more PCNA-positive cells were detected in Ptenfl/fl prostate 
hyperplasia compared to Pik3ca+/HR hyperplastic lesions (Supplementary Fig.2G), indicating 
this is an early phenomenon during disease progression. These data show that increased 
proliferation in Ptenfl/fl mice facilitates accelerated prostate cancer progression compared to 
Pik3ca+/HR mice. Notably, apoptosis evasion is not likely to contribute to accelerated disease 
progression in Ptenfl/fl mice, as the number of cleaved-caspase-3 (CC3)-positive apoptotic cells 
was largely increased in Ptenfl/fl prostate epithelium compared to age-matched Pik3ca+/HR 
mutants (Supplementary Fig.3A-B). IHC analysis to detect prostate basal and luminal cell 
markers cytokeratin-5, (CK5) and cytokeratin-8 (CK8) respectively, revealed that, unlike 
Ptenfl/fl prostate tumors, Pik3ca+/HR-driven tumors are predominantly comprised of luminal 
epithelial cells and rarely display expansion/mislocalization of the CK5-positive basal cell 
population (Supplementary Fig.3C). Taken together these data show that while a single Pik3ca 
H1047R activating mutation predisposes to murine prostate cancer, like bi-allelic loss of Pten, 
these two genetic drivers of the PI3K cascade do not completely phenocopy. Overall, these 
findings suggest that Pik3ca oncogenic mutation and Pten loss may drive prostate tumor 
phenotypes via distinct molecular mechanisms, which could present novel therapeutic targets. 
 
Pik3ca mutation and Pten loss stimulate mTORC1 signaling to promote prostate 
tumorigenesis and facilitate malignant progression in mice. Given that both Pten deletion 
and Pik3ca oncogenic mutations can activate PI3K signaling, the phenotypic differences 
observed between the genetic drivers could reflect differential activation of the PI3K cascade. 
To determine if PTEN tumor suppressive function is maintained in the Pik3ca+/HR model, we 
performed IHC to detect PTEN. We observed uniform membranous PTEN staining in Wt 
prostate epithelium and Pik3ca+/HR tumors, whereas PTEN-positive cells were absent in Ptenfl/fl 
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prostate tumors, consistent with bi-allelic Pten ablation (Fig.3C). To determine if PTEN 
impairs effector cascades downstream of PI3K in the Pik3ca+/HR model to delay prostate 
tumorigenesis and progression, we evaluated AKT activation and the status of the PI3K 
downstream mechanistic target of rapamycin (mTOR) effector cascades. mTOR is a 
serine/threonine kinase that forms part of two distinct complexes; mTORC1 and mTORC2. We 
show that the number of prostate epithelial cells displaying activation of AKT via Thr308 
phosphorylation at the cell membrane, is significantly increased in Pik3ca+/HR and Ptenfl/fl 
prostate carcinoma compared to Wt controls (Fig.3C-D), indicating that both PI3K genetic 
drivers stimulate mTORC1 signaling to promote tumor growth. In support, the proportion of 
cells displaying phosphorylation of well-known downstream mTORC1 targets, namely the 
ribosomal protein S6 (RPS6) at Ser235/236 that regulates cell size and proliferation and 4e-
binding protein 1 (4E-BP1) at Thr37/46 that mediates translational machinery, were also 
significantly elevated in both models (Fig.3C, E-F). Our analysis of the number of p-AKT 
(Thr308), p-RPS6 and p-4E-BP1 positive cells in Ptenfl/fl and Pik3ca+/HR hyperplastic lesions 
also revealed that mTORC1 signaling upregulation occurs pre-malignancy (Supplementary 
Fig.3D-G). Of note, the number of p-RPS6 and p-4E-BP1 positive cells were comparable in 
Pik3ca-mutated and Pten-deleted hyperplastic lesions and advanced tumors, despite 
significantly more p-AKT (Thr308) positive cells being detected in the Ptenfl/fl model, 
suggesting that p-AKT Thr308 independent phosphorylation of RPS6 and p4E-BP1 may occur, 
or that the partial increase in p-AKT Thr308 in Pik3ca+/HR tumors is sufficient to sustain p-
RPS6 and p-4E-BP1 signaling. Taken together, these data indicate that both Pik3ca H1047R 
oncogenic mutation and Pten bi-allelic loss stimulate mTORC1 signaling to facilitate prostate 
tumor formation and progression, and that PTEN-mediated tumor suppressive functions do not 
impair mTORC1 downstream signaling in the context of Pik3ca mutation.  
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Relative to Pik3ca mutation, Pten deletion augments mTORC2 signaling to further 
promote prostate tumor formation and progression in mice. Since activation of the 
mTORC1 downstream targets was comparable between Pik3ca+/HR and Ptenfl/fl prostate cancer 
models, we reasoned that the early onset and accelerated progression observed in the Ptenfl/fl 
model may be attributable to mTORC2 signaling. To investigate this, we performed and 
quantitated IHC in Pik3ca+/HR and Ptenfl/fl prostate carcinomas to detect the phosphorylation of 
two mTORC2 targets; AKT at Ser473 and NDRG1 at Thr346. We show that the number of p-
AKT Ser473 and p-NDRG1 Thr346 positive cells was significantly increased in Ptenfl/fl 
prostate tumors compared to the Pik3ca+/HR model and Wt controls (Fig.3C,G-H). Similar 
results were observed when comparing hyperplastic lesions (Supplementary Fig.3D,H-I). 
Thus, mTORC2 signaling presents a direct mechanism whereby Pten homozygous deletion can 
promote tumor onset/progression relative to Pik3ca H1047R oncogenic mutation in this setting.   
 
Pik3ca H1047R mutation causes p110-dependent prostate cancer. Recent reports have 
demonstrated that p110 and p110 isoforms of the PI3K catalytic subunit play distinct 
cellular functions and are regulated independently by differential binding partners(22-25). For 
instance, in vitro assays have established that Ras subfamily members can directly bind to the 
Ras binding domain (RBD) of p110 (and not p110 to activate p110 kinase activity, and 
p110 RBD:RAC1 interactions have been shown to be required for GPCR-mediated p110 
signaling(22-24). Moreover, Pten-deleted prostate cancers are considered to preferentially 
activate the p110 isoform, and p110 blockade has been shown to activate p110 owing to 
relief of feedback inhibition (e.g. via IGF1R)(25-28). Thus, we sought to determine if the 
phenotypic difference between Pten loss and Pik3ca oncogenic mutation reflects differential 
activation of PI3K catalytic isoforms. To this end, we performed IHC to detect p-ERK, a 
downstream target of the RAS cascade, and activation of RAC1 GTPase in Pik3ca+/HR and 
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Ptenfl/fl prostate tumors to distinguish activation of RAS-p110 and RAC1-p110 signaling 
axes respectively. We find that p-ERK expression is markedly elevated in Pik3ca+/HR and 
Ptenfl/fl prostate tumors compared to age-matched Wt controls, indicating p110 signaling is 
activated in both models (Fig.4A). However, only Ptenfl/fl prostate tumors displayed Active-
RAC-1 GTP staining (Fig.4B), indicating that activation of p110 signaling may promote 
prostate cancer growth induced by Pten-deletion.  
 
To directly test p110 and p110 isoform dependency in Pik3ca mutant and Pten deleted 
prostate cancers, we administered isoform specific inhibitors (A66, a p110-specific inhibitor 
or TGX-221, a p110-specific inhibitor) or a pan-PI3K inhibitor (BKM120) to cohorts of 
Pik3ca+/HR and Ptenfl/fl mice with prostate carcinoma for 4 weeks. Pik3ca+/HR tumor burden 
regressed significantly in response to A66 and BKM120 while TGX-221 had no effect, 
indicative of p110-dependency (Fig.4C). In contrast, Ptenfl/fl tumor burden was not reduced 
upon single isoform specific inhibitor treatment but did respond to BKM120 or combined A66 
and TGX-221 therapy, suggesting Pten-deleted tumors are p110/p110co-dependent 
(Fig.4D). Histopathological analysis of prostate lobes confirmed tumor regression in A66 and 
BKM120 treated Pik3ca+/HR mice, and BKM120 treated Ptenfl/fl mice (Fig.4E, Supplementary 
Fig.4A-C). These data suggest that p110mediated signaling events could facilitate Pten-
deleted prostate cancer but not Pik3ca H1047R mutated prostate cancer, and support previous 
work showing that combined p110and p110 blockade improves therapeutic outcome in 
PTEN-deficient prostate cancers compared to PI3K isoform specific monotherapy(22,26,28). 
Indeed, PI3K pathway inhibitors on their own have been shown to have limited efficacy in the 
clinic due to multiple feedback loops, PI3K-independent pathways and/or additional oncogenic 
mutations, and can cause side effects (e.g. hyperglycemia)(22,26,28,29). Thus, treatment 
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approaches that combine PI3K pathway inhibitors with other therapeutic agents are currently 
being explored to improve prostate cancer patient outcome.”  
  
Pten-deletion and Pik3ca+/HR mutation cooperate to accelerate prostate cancer 
progression in mice. Given that we have found that PIK3CA mutation and PTEN loss are not 
mutually exclusive events in prostate cancer patients, we sought to generate a new clinically 
relevant model of prostate cancer, and to test if PI3K genetic drivers can cooperate to facilitate 
prostate cancer growth. Hence, we crossed Pik3ca+/HR mutants with Ptenfl/fl animals to develop 
PBiCre+/-;Pik3ca+/HR;Ptenfl/fl compound mutants (termed Pik3ca+/HR;Ptenfl/fl) that harbour 
Pik3ca+/HR mutation and bi-allelic Pten loss in prostate epithelial cells. At 56 and 100 d we 
observed aggressive, locally invasive carcinoma with 100% incidence in all Pik3ca+/HR;Ptenfl/fl 
prostate lobes (Fig.5A-B, Supplementary Fig.5A-B, Supplementary Table 5). IHC analysis 
revealed that Pik3ca+/HR;Ptenfl/fl prostate tumors resemble Ptenfl/fl tumors, where the CK5+ 
basal cell population is expanded/mislocalized and the CK8+ luminal cells are predominant 
(Supplementary Fig.5C). Local invasion was confirmed by the absence of SMA staining 
(Supplementary Fig.5C). Tumor burden was also significantly greater in compound mutants 
than age-matched single mutants (Supplementary Fig.5D). Visceral metastases were not 
detected by 100 d of age, and the development of non-prostate malignancies reflecting leaky 
PBiCre-mediated recombination (predominantly benign buccal mucosal/cutaneous papillomas 
and penile prolapse) prevented further ageing of Pik3ca+/HR;Ptenfl/fl mice.   
 
To investigate the mechanism underpinning cooperation between Pik3ca mutation and Pten 
loss, we determined the number of proliferative and apoptotic cells in Pik3ca+/HR, Ptenfl/fl and 
Pik3ca+/HR;Ptenfl/fl locally invasive prostate carcinomas by PCNA and CC3 IHC respectively. 
We show that compound mutant tumors have significantly more PCNA-positive proliferating 
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cells than single mutants (Fig.5C-D), while CC3-mediated apoptosis is unaltered 
(Supplementary Fig.5E-F). These findings indicate that Pik3ca oncogenic mutation and Pten 
loss synergize to accelerate prostate cancer progression by increasing proliferation, but not 
survival.  
 
To ascertain if the increased proliferation in Pik3ca+/HR;Ptenfl/fl mice reflects further activation 
of mTORC1/2 signaling, we performed IHC to detect p-AKT Thr308 that leads to mTORC1 
activation, as well as the phosphorylation of known mTORC1/2 downstream signaling targets. 
Quantitation of IHC staining revealed that the number of cells expressing membranous p-AKT 
Thr308 is significantly increased in Pik3ca+/HR;Ptenfl/fl prostate carcinomas compared to stage-
matched single mutants (Fig.5E and Supplementary Fig.5G). In accordance, mTORC1 
downstream targets, p-RPS6 and p-4E-BP1 positively correlated with p-AKT Thr308 
activation (Fig.5F-G, Supplementary Fig.5G), indicating increased mTORC1 signaling 
accelerates prostate cancer growth in Pik3ca+/HR;Ptenfl/fl mutants. Phosphorylation of mTORC2 
downstream targets p-AKT Ser473 and p-NDRG1 was also significantly increased in 
compound mutants compared to single mutants (Fig.5H-I, Supplementary Fig.5G). Taken 
together, these findings suggest that further potentiation of mTORC1 and mTORC2 signaling, 
which correlates with super-activation of AKT at Thr308/Ser473, contributes to the 
cooperative relationship between Pik3ca mutation and Pten loss during prostate cancer in this 
setting.  
 
Previous work has shown that amplification/overexpression of Pik3ca and Pik3cb increases 
oncogenicity(22,30,31), and amplification frequently correlates with poor patient outcome in 
multiple malignancies(22). To establish if Pik3ca/b transcripts are expressed at physiological 
levels in Pik3ca+/HR, Ptenfl/fl and Pik3ca+/HR;Ptenfl/fl prostate carcinomas, we performed RNA 
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in situ hybridisation, and quantitated RNA molecules relative to Wt controls. We show that 
Pik3ca and Pik3cb mRNA is significantly increased in double mutant prostate tumors 
compared to Ptenfl/fl and Pik3ca+/HR single mutant tumors, and age-matched Wt controls 
(Fig.5J-L, Supplementary Fig.5H). However, the functional consequence(s) of Pik3ca and 
Pik3cb mRNA upregulation remain elusive. 
 
Pik3ca+/HR and Ptenfl/fl induced prostate cancers acquire CRPC in mice. PTEN loss is 
widely reported to correlate with resistance to androgen deprivation therapy in prostate cancer 
patients and mice(9,32,33). To examine if Pik3ca+/HR-driven prostate cancer also confers 
castration resistant disease, we aged cohorts of Pik3ca+/HR mutant mice until invasive prostate 
carcinoma had developed (300 d) and assessed the early and long-term response to surgical 
castration. Although we observed a significant reduction in Pik3ca+/HR total prostate weight at 
2 and 10 weeks post-castration (Fig.6A), histopathological analysis revealed that prostate 
tumors were still present in Pik3ca+/HR mice, indicating the development of acquired CRPC 
(Fig.6B, Supplementary Fig.6A). These findings are in keeping with partial androgen 
sensitivity and the latent acquisition of CRPC, mirroring homozygous deletion of Pten (Fig.6A 
and B, Supplementary Fig.6A), as previously reported(33,34). IHC to detect AR confirmed the 
reduction of androgens post-castration, as cytoplasmic AR was detected in Pik3ca+/HR and 
Ptenfl/fl prostate epithelial cells following castration, whereas uncastrated controls displayed 
active nuclear AR (Supplementary Fig.6B). 
 
To determine if Pik3ca heterozygous oncogenic mutation sensitises pre-neoplastic prostate 
epithelium to CRPC transition, we examined the short-term and long-term response of 
Pik3ca+/HR mice to castration at 100 d, when only hyperplastic disease is present. Prostate 
epithelial regression was detected 2 weeks post-castration and correlated with a reduction in 
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prostate weight, yet small prostate hyperplastic and dysplastic tumors, resembling uncastrated 
Pik3ca+/HR mutants, had developed by 42 weeks post-castration in 100% (6/6) and 67% (4/6) 
of cases respectively (Supplementary Fig.6C-D). These data demonstrate that Pik3ca-mutated 
prostate epithelium possesses an inherent ability to acquire CRPC, similarly to Pten loss(9). 
 
Pik3ca oncogenic mutation and Pten loss synergize, predisposing to de novo CRPC. Next, 
we castrated Pik3ca+/HR;Ptenfl/fl mice at 100 d of age when invasive carcinoma was present, to 
test if Pik3ca mutation and Pten loss can also cooperate to promote CRPC growth. At 2 weeks 
post-castration, castrated compound mutants phenocopied intact controls, and no appreciable 
difference in tumor burden was detected (Fig.6C-D). These findings contrast the partial 
regression observed in the single mutants and indicate that Pik3ca oncogenic mutation and 
Pten homozygous deletion cooperate to promote de novo CRPC in vivo. In support, single 
mutants displayed a significant reduction in the percentage of PCNA-positive proliferative cells 
and elevated CC3-positive apoptotic cells 2 weeks post-castration, which were unaltered in 
compound mutants (Fig.6E-F, Supplementary Fig.7A-B). These data indicate that de novo 
CRPC in Pik3ca+/HR;Ptenfl/fl mice is attributable to both the sustained level of proliferation and 
castration-induced apoptosis evasion. In accordance with de novo CRPC, IHC to detect AR 
also revealed that a noticeable proportion of Pik3ca+/HR;Ptenfl/fl prostate epithelial cells 
displayed AR activation (i.e. nuclear translocation) 2 weeks post-castration, which were not 
apparent in single mutants at this early time point (Supplementary Fig.6B). Of note, Nkx3.1 
and Pbsn, AR transcriptional target genes, are significantly reduced in Pik3ca+/HR prostate 
carcinomas relative to Wt prostate, and levels were further diminished in Ptenfl/fl and 
Pik3ca+/HR;Ptenfl/fl tumors (Supplementary Fig.7C-D). These findings support previous work 
indicating that PI3K activation perturbs AR-mediated signaling(29), and indicate that Pbsn and 
Nkx3.1 transcription is not likely to facilitate de novo CRPC in this setting. 
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The molecular mechanisms underpinning the emergence of CRPC are largely unknown. Pten-
deleted CRPC acquisition has been previously associated with elevated AKT signaling, 
suggesting that further activation of the AKT cascade contributes to CRPC transition(9). In 
support, we observed a significant increase in the percentage of cells positive for mTORC1 
signaling components p-AKT (Thr308), p-RPS6 (Ser235/236) and p-4E-BP1 (Thr37/46) and 
the mTORC2 target p-AKT (Ser473) in both the Pik3ca+/HR and Ptenfl/fl models just 2 weeks 
post-castration (Fig.7A-D). Notably, phosphorylation of NDRG1 was not altered in either 
model post-castration (Fig.7E). Thus, Pten-deleted and Pik3ca-mutated prostate epithelial cells 
appear to hyperactivate AKT upon castration, which elevates mTORC1 signaling downstream 
targets to facilitate CRPC transition. Nevertheless, we do not exclude the possibility that 
additional molecular events may also contribute to CRPC transition in these models, including 
PTEN and/or AKT signal transduction independent of PI3K(2,35).  
 
Our analysis of Pik3ca+/HR;Ptenfl/fl prostate tumors pre- and post-castration revealed that the 
high proportion of p-AKT (Thr308), p-RPS6 (Ser235/236) and p-AKT (Ser473) positive cells 
is maintained at a super-activated state, and that the percentage of p-4E-BP1 (Thr37/46) and p-
NDRG1 (Thr346) cells is increased even further (Fig.7A-E). Despite an increase in p-4E-BP1 
in Ptenfl/fl and Pik3ca+/HR;Ptenfl/fl castrated tumors compared to Pik3ca+/HR castrated animals, 
p-4E-BP1 was not significantly elevated in compound mutants compared to the Ptenfl/fl model, 
signifying 4E-BP1 phosphorylation at Thr37/46 and subsequent inactivation are not likely to 
promote de novo CRPC formation.  However, our findings suggest that NDRG1 inactivation 
may contribute to de novo CRPC. In addition to increased phosphorylation of NDRG1 post-
castration, androgen deprivation in Pik3ca+/HR;Ptenfl/fl  mice also positively correlated with p-
NDRG1 nuclear localisation (Fig.7F). Nevertheless, the precise role of NDRG1 inactivation 
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during de novo CRPC remains to be determined and warrants further investigation. Taken 
together, these results infer that a high threshold of AKT-hyperactivation prior to castration, 
and/or NDRG1-inactivation, may prove to be useful biomarkers of intrinsic CRPC in the clinic. 
 
To explore potential mechanisms underpinning the synergistic relationship between Pik3ca 
mutation and Pten-deletion, and during castration-resistant disease formation, we performed a 
reverse-phase protein array (RPPA) on protein lysates isolated from Pik3ca+/HR, Ptenfl/fl and 
Pik3ca+/HR; Ptenfl/fl stage-matched uncastrated prostate carcinomas, and 2-weeks post-
castration (Fig.7G, Supplementary Tables 6/7). RPPA data analysis revealed that Pik3ca-
mutated and Pten-deleted prostate tumors display distinct RPPA profiles, supporting the 
contention that Pik3ca oncogenic mutation and Pten loss may mediate distinct signaling events 
to facilitate prostate cancer growth. For instance, compared to Pik3ca+/HR tumors, Ptenfl/fl 
tumors displayed enhanced signal intensities for PI3K cascade phosphoproteins (e.g. p-AKT 
Thr308, p-AKT Ser473, p-FOXO3A Ser318/321, p-GSK-3 Ser9 and p-NDRG1 Thr346), 
whereas tyrosine kinase-mediated (p-EGFR Tyr1173, p-SHP-2 Tyr542, p-SRC family Tyr416) 
and MAPK (p-ERK1/2 Thr202/Tyr204) phosphoproteins were elevated in Pik3ca+/HR tumors 
(Fig.7G and Supplementary Table 7). Interestingly, Pik3ca+/HR and Ptenfl/fl prostate carcinomas 
did not display significant differences in RPPA signal intensities for the senescence markers 
p21 or p27 (Fig. 7G, Supplementary Table 7), suggesting that the observed phenotypic 
differences are not due to changes in senescence. A significant increase in p53 signal intensity 
was observed in Ptenfl/fl tumors relative to Pik3ca+/HR tumors. As p21 and p27 are unaltered, 
these findings indicate that the observed changes in p53 are not regulating senescence, but may 
instead be mediating other cellular functions, such as apoptosis. This correlates with our 
observations in CC3 and phosphorylated p53 (Ser15) (Fig.7G, Supplementary Fig.3B, 
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Supplementary Table 7).  RPPA results for p-AKT Thr308 and p-AKT Ser473 were confirmed 
by Western blotting (Supplementary Fig.7E).  
 
RPPA profiles for uncastrated and castrated compound mutants were strikingly similar. Indeed, 
only 4 targets were significantly altered; p-SHP-2 (Tyr542) and p-SRC family (Tyr416) signals 
were increased and YAP and CK2 were decreased (Fig.7G, Supplementary Table 7). This 
result contrasts single mutants that acquired CRPC and is consistent with the general lack of 
effect of castration on the prostate tumors in the double mutant mice (Fig.6C-F). However, it 
should be noted that the RPPA was not sensitive enough to detect elevated p-NDRG1 (Thr346) 
in Pik3ca+/HR;Ptenfl/fl mutants post-castration that was observed by IHC (Fig.7E-F), presumably 
owing to tumor heterogeneity and/or stromal content, which may also be a contributing factor 
in the lack of significant difference in other proteins as well. Nevertheless, distinct differences 
between the Pik3ca+/HR and Ptenfl/fl models were detected post-castration (Fig.7G, 
Supplementary Table 7). For instance, Pik3ca-mutated tumors displayed a significant increase 
in IGF1R and p-NF-kB p65 (Ser 536) signal intensities post-castration, which were not altered 
in Pten-deleted tumors post-castration. Additionally, castrated Pik3ca+/HR tumors displayed 
elevated JAK/STAT and MAPK signaling relative to castrated Ptenfl/fl tumors. Taken together, 
our findings suggest that Pik3ca oncogenic mutation and Pten loss may mediate distinct 
signaling events to facilitate prostate cancer growth and resistance to castration.  
 
Discussion 
We report that PIK3CA mutation/amplification positively correlates with poor prostate cancer 
patient prognosis and overall survival. Our findings are the first to demonstrate that the PIK3CA 
H1047R oncogenic mutation is sufficient to cause invasive prostate cancer in vivo and that 
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concomitant loss of PTEN and PIK3CA mutation, which frequently occurs in the clinic, can 
cooperate to accelerate prostate cancer growth in mice.  
 
Our data support the hypothesis that different genetic drivers of the PI3K cascade are not 
functionally redundant, but instead drive prostate tumorigenesis via distinct signaling events. 
We show that relative to p110-dependent Pik3ca+/HR-induced prostate cancers, Ptenfl/fl 
prostate tumors are p110/ co-dependent, and exhibit accelerated tumor formation and 
progression owing to AKT-hyperactivation, elevated mTORC2 and RAC1-p110 signaling. 
The failure to induce robust AKT signaling in Pik3ca+/HR epithelium is probably attributable 
to the maintenance of PTEN tumor suppressive function that reduces PIP3 levels, AKT 
membrane recruitment, and subsequent activation of AKT, as previously reported(35). In 
corroboration, Pten loss has been shown to positively correlate with disease progression in 
mice, as Pten loss of heterozygosity is required for prostate cancer growth in Pten heterozygous 
prostate epithelium(9). We speculate that PTEN function is also likely to be conserved in 
transgenic mice expressing myristoylated/activated AKT or p110 in prostate epithelial cells, 
as only low-grade prostate epithelial neoplasia develops that does not progress to carcinoma 
with ageing(36,37). Taken together, these observations suggest that additional 
mTORC2/RAC1/p110-independent cooperative events are likely to facilitate malignant 
progression to an invasive state in Pik3ca+/HR mutants that express PTEN. Indeed, PIK3CA 
mutations have been shown to potentiate a PDK1-SGK3, AKT-independent signaling axis in 
various human cancer cell lines that express PTEN(35), and PDK1-SGK1 AKT-independent 
signaling has been shown to cause resistance to p110 inhibition by directly phosphorylating 
TSC2 to activate the mTORC1 pathway(38).  
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Guertin and colleagues have previously shown that RICTOR, a key regulatory component of 
mTORC2, is required for PC3 PTEN-null human prostate cancer cells to form tumor 
xenografts, and that bi-allelic deletion of Rictor prevents prostate cancer formation driven by 
Pten loss in mice by reducing proliferation and AKT phosphorylation at Ser473(39). We show 
that Ptenfl/fl mice displayed early prostate tumor formation and accelerated progression relative 
to Pik3ca+/HR mutants, reflecting elevated mTORC2 signalling and subsequent AKT 
phosphorylation at Ser473 in the context of Pten loss. Thus, our findings support the notion 
that mTORC2 signalling plays a critical role during prostate tumorigenesis and progression, 
and strengthen the rationale for mTORC2-targeted therapy in PTEN-deleted prostate cancer. 
 
The absence of p-AKT Ser473 phosphorylation in Pik3ca+/HR mutant prostate cancer may be 
attributable to reduced PIP3 levels and/or distinct AKT regulation in Pten-null and Pik3ca 
mutant prostate cancers, as AKT phosphorylation is dependent on a plethora of AKT protein 
kinases and phosphatases(5). Of note, the mechanism of AKT regulation may also depend upon 
the type of PIK3CA mutation (i.e. helical vs kinase) and tissue context, as several human cancer 
cell lines with PIK3CA kinase mutations have been shown to express high levels of p-AKT 
Ser473 and Thr308 in the presence of PTEN(35). PTEN is also reported to play a broader AKT-
independent tumor suppressive role via protein- and lipid-phosphatase activities to mediate 
p53, cell cycle arrest and integrin, insulin and focal adhesion kinase signaling, reviewed in(40). 
Thus, developing our combined understanding of AKT regulation, p110 PI3K isoform 
signaling, and PTEN mode of action during prostate cancer is vital to determine optimal 
therapeutic approaches that inhibit the PI3K signaling network and subsequently prostate 
cancer growth and progression.  
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Although p110 and p110β isoforms have been shown to form mutually exclusive signaling 
complexes with RAS and RHO family (RAC1/CDC42) small GTPase protein superfamily 
members respectively(22), the molecular mechanisms underpinning their different modes of 
action are poorly understood. This study provides additional data that underlines a distinct role 
for the RAC1-p110 signaling axis in Pten-deleted prostate cancer, and raises the possibility 
that RAC inhibition may show therapeutic efficacy against PTEN-deleted prostate cancer in 
the clinic, as recently demonstrated for a Pten-null, p110-dependent mouse model of myeloid 
neoplasia(41). By taking this approach, PI3K-independent functions of PTEN and AKT may 
be advantageously co-targeted, as RAC1 activation is mediated by PI3K-dependent (e.g. 
PREX-1/TIAM/mTORC2) and PI3K-independent (e.g. SRC/p130CAS) signaling(25,42).   
 
We have generated a new clinically relevant transgenic mouse model of advanced prostate 
cancer driven by concomitant Pik3ca heterozygous oncogenic mutation and Pten homozygous 
deletion. We show that these two oncogenic drivers cooperate to promote rapid progression to 
invasive prostate cancer, characterised by the synergistic elevation of mTORC1/2 signaling, 
AKT super-activation and increased Pik3ca/b mRNA transcript expression. These data provide 
direct evidence that Pik3ca mutation and Pten deletion coordinate independent oncogenic 
signaling events during prostate cancer, in corroboration with the distinct RPPA profiles 
observed. Furthermore, our findings emphasize that the co-existence of mutated PIK3CA and 
PTEN loss may prove to be an important prognostic indicator for rapid prostate cancer 
progression and de novo resistance to androgen deprivation therapy in the clinic.  
 
Currently, the cause and consequence of upregulated Pik3ca/b transcription is poorly 
understood. Theoretically, increased Pik3ca/b gene expression could promote prostate cancer 
progression in Pik3ca+/HR;Ptenfl/fl  mice by increasing p110 protein levels, and thus total 
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PI3K activity, as PIK3CA amplification is thought to do in ovarian cancer cells (43). FOXO3A, 
NF-kB, YB1 and p53 have been shown to promote PIK3CA transcription (reviewed in(44)), 
however PIK3CB transcriptional regulators remain to be identified. Further investigation is 
needed to determine the underlying mechanism by which increased p110 catalytic activity and 
loss of Pten phosphatase activity cooperate to upregulate Pik3ca and Pik3cb transcription, and 
to establish the functional significance of this observation.  
 
Despite numerous phenotypic differences, we report that both Pten-null and Pik3ca+/HR-driven 
prostate cancers are partially sensitive to androgen withdrawal and acquire CRPC in 
association with augmented PI3K signaling. These data signify that both p110 and p110  
PI3K catalytic isoforms can induce PI3K signaling in response to androgen deprivation, 
supporting previous in vitro work in the PTEN-deficient human prostate cancer LNCaP cell 
line that showed PI3K signaling induced by an AR-inhibitor is diminished by p110 or p110 
inhibition(26). Since, AKT-hyperactivation and augmented mTORC1/2 are consistent features 
of intact Pik3ca+/HR;Ptenfl/fl prostate tumors, it is tempting to speculate that AKT-
hyperactivation may be a pre-requisite for de novo CRPC in this setting. In addition, innate 
CRPC in Pik3ca+/HR;Ptenfl/fl compound mutants was associated with increased phosphorylation 
of the mTORC2-SGK substrate NDRG1 at Thr346, suggesting that NDRG1 inactivation may 
facilitate de novo CRPC. Significantly, NDRG1 has been shown to function as a metastasis 
suppressor in mouse xenograft models of prostate cancer by reducing Activating Transcription 
Factor 3 (ATF3) transcription, and NDRG1 mRNA down-regulation correlates with Gleason 
score and worse prostate cancer survival(45). Stein and colleagues have also reported that 
NDRG1 is a p53 transcriptional target that is required for p53-mediated apoptosis(46). Given 
that Pik3ca+/HR;Ptenfl/fl prostate tumors evade castration-induced apoptosis and proliferation 
arrest, it will be important for future studies to determine if NDRG1 inactivation contributes to 
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CRPC transition. However, since oncogenic PI3K/AKT signaling has been linked to increased 
genomic instability(47), we do not exclude the possibility that Pik3ca+/HR;Ptenfl/fl prostate 
tumors create an environment capable of inducing additional oncogenic mutations that promote 
CRPC formation.  
 
It is becoming clear that approaches inhibiting multiple targets within the PI3K network, either 
simultaneously or sequentially, are necessary to enhance therapeutic efficacy. Thus, further 
characterization of p110-mediated signaling, PI3K-independent PTEN tumor suppressive 
functions, AKT-independent signaling and AKT regulation is required to improve our 
understanding of how to target the PI3K network and identify mechanisms of therapeutic 
resistance to improve our management of prostate cancer in the clinic. Future work addressing 
how to personalise treatment for tumors driven by diverse PI3K genetic drivers is paramount, 
and is likely to entail the co-inhibition of PI3K-dependent and PI3K/AKT-independent 
signaling pathways.   
 
Materials and Methods 
 
Experimental animals: PBiCre transgenic mice that express Cre recombinase under the control 
of the Probasin promoter and Ptenfl/fl mice have been described previously(21,48). Pik3caH1047R 
mutant mice were generated in-house(11). All mice were maintained on a pure FVB/NJ 
background. Mice were genotyped from DNA isolated from toe biopsies, as described 
previously(11,49). Age-matched males were randomly assigned to uncastrated/castrated 
cohorts. Castration experiments involved the surgical removal of the testis and epididymis. 
Animal experiments followed the National Health and Medical Research Council (NHMRC) 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes and were 
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approved by the Animal Experimentation Ethics Committee at Peter MacCallum Cancer 
Centre.  
 
Tissue isolation and histology: Tissue was harvested and fixed for 16-24 h in 10% neutral-
buffered formaldehyde at 4C before being paraffin embedded and sectioned at 4 m. Sections 
were stained with haematoxylin/eosin for histological analysis by a certified pathologist (P.W.) 
blinded to genotype/treatment. Defining characteristics for prostate disease were based upon 
the pathological classification of mouse prostate disease outlined in (50). 
 
Immunohistochemistry: Staining was carried out as described previously(49) on formalin-
fixed, paraffin-embedded (FFPE) sections. Primary antibodies: Active RAC1-GTP 1:800 
(#26903, NewEast Biosciences), AR 1:300 (#sc-816, Santa Cruz), PCNA 1:400 (#610665, BD 
Biosciences Pharmingen), and Cell Signalling Technology antibodies: Cleaved Caspase-3 
1:300 (#9664), p-AKT (Ser473) 1:400 (#4060), p-AKT (Thr308) 1:400 (#13038), p-ERK 
(Thr202/Tyr204) 1:200 (#4376), PTEN 1:300 (#9559), p-RPS6 (Ser235/236) 1:400 (#2211), 
p-NDRG1 (Thr346) 1:800 (#5482) and p-4E-BP1 (Thr37/46) 1:200 (#2855). IHC scoring 
represents the mean percentage of positive cells counted from 8-10 images/mouse (200x 
magnification, BX-51 Olympus microscope, n=3/genotype).  
 
PI3K inhibitor administration: Cohorts of male Pik3ca+/HR or Ptenfl/fl mice were treated at 400 
and 200 d old respectively: A66 (p110-specific inhibitor, 100 mg/kg, daily p.o.), TGX-221 
(p110-specific inhibitor, 30 mg/kg, daily p.o.) and BKM120 (pan-PI3K inhibitor, 40 mg/kg, 
daily p.o.). Inhibitors were dissolved in filter-sterilised 20% hydroxyproyl-beta-cyclodextrin 
(Sigma), sonicated for 10 minutes and dosed immediately (4 weeks; 5 d on, 2 d off). No 
appreciable toxicity was observed (i.e. >20% weight loss). A66 and TGX-221 were generated 
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in house by P.R.S. (University of Auckland, New Zealand) and BKM120 was obtained from 
SYNkinase (Australia).  
 
RNA in situ hybridisation: FFPE mouse prostate tissue sections were probed using the 
RNAscope® 2.5 high-definition red detection kit (#322350, Advanced Cell Diagnostics). 
Slides were counterstained with hematoxylin. Scoring represents the average number of RNA 
molecules per 50 cells/mouse (400x magnification, BX-43 Olympus microscope, 
n=3/genotype). 
 
RPPA: Protein lysates were prepared from snap frozen tissue homogenized in CLB1 buffer 
(Zeptosens, Bayer), and quantified using a Pierce™ Coomassie Plus (Bradford) Protein Assay 
Kit (n=3/cohort). Using a Sciclone/Caliper ALH3000 liquid handling robot (Perkin Elmer), 
samples were serially diluted in 10% CLB1:90% CSBL1 buffer (Zeptosens, Bayer) and spotted 
onto ZeptoChips (Zeptosens) in duplicate using a Nano-plotter-NP2.1 non-contact microarray 
system (GeSim). Chips were blocked under non-contact conditions for 1 hour with BB1 buffer 
(Zeptosens), incubated with pre-validated primary antibodies (1:500, 20 hours), and Alexa 
Fluor® 647 anti-rabbit secondary antibody (1:1000, 4 hours) (#Z-25308, Thermo Fisher 
Scientific). Chips were read on a Zeptosens instrument and software version 3.1 used to calculate 
the relative fluorescence intensity. All samples were normalised to the background values reported 
in the secondary antibody-only negative control. Pearson’s correlation was calculated to confirm 
replicate pairs were adequately correlated (correlation coefficient >0.9). Data were Log2-
normalised, median centered and re-scaled between 0-1 using the formula; 
𝑎𝑏−min(𝑎𝑏)
max(𝑎𝑏)−min⁡(𝑎𝑏)
. 𝑎𝑏 
represents a vector of antibody responses for a given sample. The RPPA heatmap was 
generated in R using pheatmap.  
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Analysis of genomic datasets: Analysis of PIK3CA gene mutation/amplification was performed 
on prostate cancer patient datasets with sequencing and copy number alteration (CNA) data 
using the cBioPortal platform(14). The TCGA provisional dataset was downloaded from the 
TCGA data portal (https://tcga-data.nci.nih.gov/); PIK3CA segment mean Log R-Ratio ≥0.135. 
To minimise CNA noise, probe number was filtered to ≤10. Silent mutations were excluded. 
 
Statistical analysis: Prostate weight and IHC scoring were analysed using a one-way ANOVA 
with Tukey’s correction or an unpaired t-test (95% confidence interval) as indicated using 
GraphPad Prism_7.03 software. Kaplan-Meier plots were generated, and age-adjusted COX 
proportional hazard regression ratio calculated using R software. For RPPA, an unpaired two-
tailed t-test with Welch’s correction was calculated using R software. P<0.05 was considered 
statistically significant.   
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Figure legends 
 
Figure 1. PIK3CA somatic mutation and amplification frequency in prostate cancer. (A) 
Histogram displaying PIK3CA mutation and copy number amplification/gain frequency across 
9 prostate cancer genomic datasets. Pie charts show the distribution of primary and metastatic 
samples for each genomic dataset. (B) Schematic diagram of p110 illustrating mutation 
frequency across the 9 prostate cancer datasets analysed in relation to the core functional 
domains. Codons with frequent missense mutations at common hotspots are labelled magenta. 
To our knowledge, the 4 genetic alterations in light grey text have not been previously reported 
in other human malignancies, and their impact on p110 function is unknown. p85 = PI3K p85 
regulatory subunit binding domain; RBD = RAS binding domain; C2 = calcium-dependent 
phospholipid-binding domain; Helical = PI3K helical domain; Kinase = PI3/4-kinase domain; 
aa = amino acid. (C) Kaplan-Meier plot comparing the survival probability of PIK3CA 
mutation and/or amplification/gain carriers with PIK3CA unaltered patients within the TCGA 
provisional prostate cancer patient dataset. PIK3CA age-adjusted COXPH HR: 0.55, 
*P=0.023*. 
 
Figure 2. Heterozygous Pik3caH1047R oncogenic mutation causes invasive prostate cancer 
in mice that does not phenocopy Pten-deletion. (A) Representative H&E images of Wt, 
Pik3ca+/HR and Ptenfl/fl dorsolateral prostate epithelium (scale bar: 100 m). (B) Histogram 
displaying phenotype incidence in Wt, Pik3ca+/HR and Ptenfl/fl dorsolateral prostate. DLP = 
dorsolateral prostate, PIN = prostate intraepithelial neoplasia. (C) Bar chart displaying total 
prostate weight normalised to body weight for Wt, Pik3ca+/HR and Ptenfl/fl mice. n = as indicated 
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(N). Error bars: SEM, *P<0.05 compared to Wt, one-way ANOVA with Tukey’s multiple 
comparison test.    
 
Figure 3. Pten deletion triggers mTORC2 signaling to facilitate rapid prostate cancer 
progression relative to Pik3caH1047R mutation. (A) IHC to detect the proliferation marker 
PCNA in Wt, Pik3ca+/HR and Ptenfl/fl prostate carcinoma at 400 d of age (scale bar: 50 m). (B) 
Quantitation of PCNA-positive nuclei in Wt, Pik3ca+/HR and Ptenfl/fl prostate epithelium (n=3, 
*P<0.05 compared to Wt, or as indicated, one-way ANOVA with Tukey’s multiple comparison 
test. Error bars: SEM). (C) Representative IHC images to detect PTEN, mTORC1 signaling 
components (p-AKT Thr308, p-RPS6 Ser235/236 and p-4E-BP1 Thr37/46) and mTORC2 
substrates (p-AKT Ser473 and p-NDRG1 Thr346) in Wt dorsolateral prostate and Pik3ca+/HR 
and Ptenfl/fl prostate carcinoma at 400 d of age (n=3, scale bar: 50 m, insert scale bar: 10 m). 
IHC quantitation for (D) p-AKT Thr308, (E) p-RPS6 Ser235/236, (F) p-4E-BP1 Thr37/46, (G) 
p-AKT Ser473 and (H) p-NDRG1 Thr346 in Wt dorsolateral prostate and Pik3ca+/HR and 
Ptenfl/fl prostate carcinoma at 400 d of age (n=3, Error bars: SEM, *P< 0.05 compared to Wt, 
or as indicated, one-way ANOVA with Tukey’s multiple comparison correction). 
 
Figure 4. Pik3ca+/HR prostate cancer is p110-dependent, whereas Ptenfl/fl prostate cancer 
is p110 and p110  co-dependent. Representative IHC images to detect (A) p-ERK 
Thr202/Tyr204 and (B) Active RAC1-GTP in Wt dorsolateral prostate and Pik3ca+/HR and 
Ptenfl/fl prostate carcinoma at 400 d of age (n=3, Low magnification scale bar: 100 m, high 
magnification scale bar: 10 m). Bar chart indicating total prostate weight normalised to body 
weight for Pik3ca+/HR mice (C) and Ptenfl/fl mice (D) with prostate carcinoma administered with 
either vehicle, p110-specific inhibitor (A66), p110-specific inhibitor (TGX-221), pan-PI3K 
inhibitor (BKM120) or A66 + TGX-221 for 4 weeks compared to age-matched Wt controls. n 
Pik3ca mutation drives prostate cancer 
36 
 
= as indicated (N). Error bars: SEM, *P<0.05 compared to vehicle, one-way ANOVA with 
Tukey’s multiple comparison correction, ns = not significant. (E) Histogram displaying 
phenotype incidence for dorsolateral prostate from Pik3ca+/HR and Ptenfl/fl mice treated with 
either vehicle, p110-specific inhibitor (A66), p110-specific inhibitor (TGX-221), pan-PI3K 
inhibitor (BKM120) or A66 + TGX-221 for 4 weeks. 
 
Figure 5. Pik3ca mutation and Pten loss cooperate to accelerate prostate cancer 
progression in mice by upregulating proliferation and mTORC1/2 signaling. (A) 
Representative IHC images of Pik3ca+/HR;Ptenfl/fl prostate carcinoma at 56 and 100 d of age 
(scale bar: 100 m). (B) Phenotype incidence histogram for Wt, Pik3ca+/HR, Ptenfl/fl and 
Pik3ca+/HR;Ptenfl/fl dorsolateral prostate at 56 and 100 d of age. (C) IHC to detect PCNA in 
Pik3ca+/HR, Ptenfl/fl and Pik3ca+/HR;Ptenfl/fl stage-matched prostate carcinomas (scale bar: 50 
m). IHC quantitation for (D) PCNA, (E) p-AKT Thr308, (F) p-RPS6 Ser235/236, (G) p-4E-
BP1 Thr37/46, (H) p-AKT Ser473 and (I) p-NDRG1 Thr346 in Pik3ca+/HR, Ptenfl/fl and 
Pik3ca+/HR;Ptenfl/fl stage-matched prostate carcinomas (n=3, *P<0.05 compared to Pik3ca+/HR 
or as indicated, one-way ANOVA with Tukey’s correction. Error bars: SEM). (J) RNA in situ 
hybridisation analysis of Pik3ca and Pik3cb transcripts in Pik3ca+/HR, Ptenfl/fl and 
Pik3ca+/HR;Ptenfl/fl stage-matched prostate carcinomas (n=3, scale bar: 50 m, insert scale bar: 
5 m). Quantitation of (K) Pik3ca and (L) Pik3cb mRNA molecules detected by in situ 
hybridisation in Pik3ca+/HR, Ptenfl/fl and Pik3ca+/HR;Ptenfl/fl stage-matched prostate carcinomas 
(n=3, *P<0.05 compared to Wt, one-way ANOVA with Tukey’s correction. Error bars: SEM). 
 
Figure 6. Pik3ca+/HR and Ptenfl/fl prostate cancers acquire CRPC, while Pik3ca+/HR;Ptenfl/fl 
compound mutants display innate resistance to castration. (A) Bar chart displaying total 
prostate weight normalised to body weight for Pik3ca+/HR and Ptenfl/fl mice 2 and 10 weeks 
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post-castration relative to age-matched/uncastrated controls. n = as indicated (N). Error bars: 
SEM, *P<0.05, one-way ANOVA with Tukey’s correction. (B) Representative H&E images 
of Pik3ca+/HR and Ptenfl/fl uncastrated dorsolateral prostate, and 2 and 10 weeks post-castration 
(scale bar: 100 m). (C) Representative H&E images of Pik3ca+/HR;Ptenfl/fl uncastrated 
dorsolateral prostate and 2 weeks post-castration (scale bar: 100 m, n = 5). (D) Bar chart 
displaying total prostate weight normalised to body weight for Pik3ca+/HR:Ptenfl/fl mice 2 weeks 
post-castration relative to age-matched/uncastrated controls (Error bars: SEM, P=0.3394, 
unpaired, two-tailed t-test, n = 5). IHC quantitation for (E) PCNA and (F) Cleaved-Caspase 3 
(CC3) in Pik3ca+/HR, Ptenfl/fl and Pik3ca+/HR;Ptenfl/fl dorsolateral prostate 2 weeks post-
castration compared to uncastrated/age-matched controls. Error bars: SEM, *P<0.05, one-way 
ANOVA with Tukey’s correction, n = 3. Mice were castrated when prostate carcinoma was 
prevalent; Pik3ca+/HR = 400 d old, Ptenfl/fl = 200 d old and Pik3ca+/HR;Ptenfl/fl =100 d old. 
  
Figure 7. De novo CRPC in Pik3ca+/HR;Ptenfl/fl double transgenic animals correlates with 
NDRG1 inactivation. Quantitation of IHC to detect mTORC1 signaling components (A) p-
AKT Thr308, (B) p-RPS6 Ser235/236, (C) p-4E-BP1 Thr37/46, (D) p-AKT Ser473 and (E) p-
NDRG1 Thr346 in Pik3ca+/HR, Ptenfl/fl and Pik3ca+/HR;Ptenfl/fl prostate tissue 2 weeks post-
castration compared to uncastrated, age-matched controls (n = 3, Error bars: SEM, *P<0.05, 
one-way ANOVA with Tukey’s multiple comparison correction). (F) Representative IHC 
images of p-NDRG1 Thr346 in Pik3ca+/HR, Ptenfl/fl and Pik3ca+/HR;Ptenfl/fl prostate tissue 2 
weeks post-castration compared to uncastrated, age-matched controls (scale bar: 50 m, n = 
3). (G) RPPA analysis was performed on lysates from Pik3ca+/HR, Ptenfl/fl and 
Pik3ca+/HR;Ptenfl/fl prostate tissue 2 weeks post-castration, and compared to uncastrated, age-
matched controls. Heatmap represents Log2 normalised and median centred data (means of 
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duplicates, n = 3 per cohort). Mice were castrated when prostate carcinoma was prevalent; 
Pik3ca+/HR = 400 d old, Ptenfl/fl = 200 d old and Pik3ca+/HR;Ptenfl/fl =100 d old. 
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